Lewis Zhichang Shi

9PUBLICATIONS
26CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 15, 2025
Gfi1 controls the formation of effector-like CD8+ T cells during chronic infection and cancer.

Oluwagbemiga A Ojo, Hongxing Shen, Jennifer T Ingram

|Feb 12, 2025
PTP Inhibition Improves the Macrophage Antitumor Immune Response and the Efficacy of Chemo- and Radiotherapy.

Nestor Prieto-Dominguez, Paran Goel, Oluwagbemiga A Ojo

|Oct 31, 2024
HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells.

Hongxing Shen, Oluwagbemiga A Ojo, Haitao Ding

|Apr 25, 2024
Gfi1 controls the formation of effector CD8 T cells during chronic infection and cancer.

Oluwagbemiga A Ojo, Hongxing Shen, Jennifer T Ingram

|Jan 23, 2024
HIF1α-glycolysis engages activation-induced cell death to drive IFN-γ induction in hypoxic T cells.

Hongxing Shen, Logan Mullen, Oluwagbemiga A Ojo

|Jan 14, 2023
HiJAKing Immunotherapy-Resistant Melanoma for a Cure.

Lewis Zhichang Shi, Hongxing Shen, Oluwagbemiga A Ojo

Pageof 2